Intelligent Bio Company Insiders
| INBS Stock | USD 1.76 0.18 11.39% |
Intelligent Bio employs about 50 people. The company is managed by 4 executives with a total tenure of roughly 117 years, averaging almost 29.0 years of service per executive, having 12.5 employees per reported executive. Breaking down Intelligent Bio's management performance can provide insight into the firm performance.
Intelligent |
Intelligent Bio Management Team Effectiveness
The company has return on total asset (ROA) of (0.5326) % which means that it has lost $0.5326 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7171) %, meaning that it created substantial loss on money invested by shareholders. Intelligent Bio's management efficiency ratios could be used to measure how well Intelligent Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.02 in 2025. Return On Capital Employed is likely to gain to -1.35 in 2025. At this time, Intelligent Bio's Other Current Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 1 M in 2025, whereas Total Current Assets are likely to drop slightly above 6.5 M in 2025.Common Stock Shares Outstanding is likely to gain to about 3 M in 2025, whereas Net Loss is likely to drop (10 M) in 2025.
Intelligent Bio Workforce Comparison
Intelligent Bio Solutions is currently regarded as number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 38,634. Intelligent Bio adds roughly 50.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Intelligent Bio Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Intelligent Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Intelligent Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Intelligent Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sakiris Spiro Kevin over two months ago Insider Trading | ||
Sakiris Spiro Kevin over six months ago Disposition of 9394 shares by Sakiris Spiro Kevin of Intelligent Bio subject to Rule 16b-3 | ||
Life Science Biosensor Diagnostics Pty Ltd over a year ago Sale by Life Science Biosensor Diagnostics Pty Ltd of 576028 shares of Intelligent Bio | ||
Towers Christopher over a year ago Purchase by Towers Christopher of 9090 shares of Intelligent Bio | ||
Sakiris Spiro Kevin over a year ago Intelligent Bio exotic insider transaction detected | ||
Sakiris Spiro Kevin over a year ago Intelligent Bio exotic insider transaction detected |
Intelligent Bio Notable Stakeholders
An Intelligent Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Intelligent Bio often face trade-offs trying to please all of them. Intelligent Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Intelligent Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Harry Simeonidis | President CEO | Profile | |
| BBus CA | Chief Officer | Profile | |
| Alex Arzeno | VP Relations | Profile | |
| Victoria Gavrilenko | Operations Manager | Profile |
About Intelligent Bio Management Performance
The success or failure of an entity such as Intelligent Bio Solutions often depends on how effective the management is. Intelligent Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Intelligent management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Intelligent management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.97) | (1.02) | |
| Return On Capital Employed | (1.42) | (1.35) | |
| Return On Assets | (0.66) | (0.70) | |
| Return On Equity | (1.40) | (1.33) |
Please note, the imprecision that can be found in Intelligent Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Intelligent Bio Solutions. Check Intelligent Bio's Beneish M Score to see the likelihood of Intelligent Bio's management manipulating its earnings.
Intelligent Bio Workforce Analysis
Traditionally, organizations such as Intelligent Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Intelligent Bio within its industry.Intelligent Bio Manpower Efficiency
Return on Intelligent Bio Manpower
| Revenue Per Employee | 62.2K | |
| Revenue Per Executive | 777.9K | |
| Net Loss Per Employee | 203.8K | |
| Net Loss Per Executive | 2.5M | |
| Working Capital Per Employee | 61.7K | |
| Working Capital Per Executive | 770.9K |
Additional Tools for Intelligent Stock Analysis
When running Intelligent Bio's price analysis, check to measure Intelligent Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intelligent Bio is operating at the current time. Most of Intelligent Bio's value examination focuses on studying past and present price action to predict the probability of Intelligent Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intelligent Bio's price. Additionally, you may evaluate how the addition of Intelligent Bio to your portfolios can decrease your overall portfolio volatility.